期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 91, 期 2, 页码 303-309出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2011.244
关键词
-
资金
- National Institutes of Health/National Institute of Mental Health (NIH/NIMH) [1K23MH094707-01]
- National Alliance for Research on Schizophrenia and Depression (NARSAD)
- American Foundation for Suicide Prevention [YIG-0-10-223]
- Mount Sinai School of Medicine
- AstraZeneca to Mount Sinai
- Dean of Mount Sinai School of Medicine
Recent reports of a rapid antidepressant effect of the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine, even in treatment-resistant populations, have spurred translational therapeutic and neuroscience research aimed at elucidating ketamine's mechanism of action. This article provides a concise overview of research findings that pertain to the effects of low-dose ketamine at the cellular, neurocircuitry, and behavioral levels and describes an integrated model of the action of ketamine in the treatment of depression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据